{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:47:10Z","timestamp":1793083630901,"version":"4.5.0"},"reference-count":60,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["TWINSIGHT-12"],"award-info":[{"award-number":["TWINSIGHT-12"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["945393"],"award-info":[{"award-number":["945393"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,11,15]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative modality in the treatment of patients with cancer. However, it is increasingly evident that this therapeutic approach is not without its challenges. The unique nature of CAR-T cells as living drugs introduces a distinct set of side effects. As the application of CAR-T cell therapy expands to treat a broader range of diseases, it becomes increasingly important to devise effective strategies for handling the associated toxicities. Challenges in treating patients with CAR-T cells include addressing complications such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and cytopenias. This comprehensive review seeks to systematically identify, categorize and elucidate all previously described neurological and psychological side effects associated with CAR-T cell therapy, shedding light on the pertinent laboratory findings that underscore these phenomena.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed, Springer Link, and ScienceDirect were systematically searched for empirical studies on adult patients with cancer receiving CAR-T cell therapy for hemato-oncological malignancies. Quality assessment was conducted using Version 2 of the Cochrane risk-of-bias tool (RoB 2) for randomized trials and adherence to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist for observational studies. The synthesis of findings was conducted via a narrative approach, consolidating the diverse array of data into a coherent framework.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From an initial pool of 2,276 citations, 546 studies met the inclusion criteria, exhibiting a rich tapestry of heterogeneity in terms of study characteristics and patient samples. The incidence of neuropsychological symptoms varied notably across different CAR-T cell products and hematological malignancies. Among the most frequently reported neuropsychological symptoms were aphasia, attention deficits, impaired consciousness, and disorientation, alongside a constellation of other symptoms including confusion, cognitive impairment, memory loss, writing difficulties, fatigue, headache, agitation, tremor, seizures, and psychomotor retardation. Early intervention strategies, including corticosteroids and tocilizumab, have shown the potential to reduce the intensity of neuropsychological symptoms and prevent their progression to critical complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These insights underscore the imperative of extending neuropsychological assessments beyond the conventional Immune Effector Cell-Associated Encephalopathy score framework.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-009174","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T09:40:46Z","timestamp":1734860446000},"page":"e009174","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies"],"prefix":"10.1136","volume":"12","author":[{"given":"Anna","family":"Fleischer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Kurth","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Topp","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Sanges","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-1182","authenticated-orcid":false,"given":"Imad","family":"Maatouk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"2025100306472086000_12.12.e009174.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100306472086000_12.12.e009174.2","doi-asserted-by":"crossref","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of Manufacturing Procedures on CAR T Cell Functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"2025100306472086000_12.12.e009174.3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14712598.2023.2248878","article-title":"Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma","volume":"23","author":"Saha","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025100306472086000_12.12.e009174.4","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMc2309399","article-title":"Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"Zhao","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100306472086000_12.12.e009174.5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2021014892","article-title":"Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia","volume":"140","author":"Frey","year":"2022","journal-title":"Blood"},{"key":"2025100306472086000_12.12.e009174.6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025100306472086000_12.12.e009174.7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2023","journal-title":"haematol"},{"key":"2025100306472086000_12.12.e009174.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1358\/dot.2023.59.1.3509751","article-title":"Ciltacabtagene autoleucel for the treatment of multiple myeloma","volume":"59","author":"Holstein","year":"2023","journal-title":"Drugs Today (Barc)"},{"key":"2025100306472086000_12.12.e009174.9","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025100306472086000_12.12.e009174.10","doi-asserted-by":"crossref","unstructured":"Adkins, RN, MSN, ANP-C S . CAR T-Cell Therapy: Adverse Events and Management. JADPRO 2019;10. doi:10.6004\/jadpro.2019.10.4.11","DOI":"10.6004\/jadpro.2019.10.4.11"},{"key":"2025100306472086000_12.12.e009174.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.478"},{"key":"2025100306472086000_12.12.e009174.12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2017-161"},{"key":"2025100306472086000_12.12.e009174.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-024-04851-0","article-title":"Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update","volume":"28","author":"Bellal","year":"2024","journal-title":"Crit Care"},{"key":"2025100306472086000_12.12.e009174.14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100306472086000_12.12.e009174.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10237-3"},{"key":"2025100306472086000_12.12.e009174.16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100306472086000_12.12.e009174.17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2025100306472086000_12.12.e009174.18","doi-asserted-by":"crossref","unstructured":"Xiao X , Huang S , Chen S , et al . Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res 2021;40. doi:10.1186\/s13046-021-02148-6","DOI":"10.1186\/s13046-021-02148-6"},{"key":"2025100306472086000_12.12.e009174.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100306472086000_12.12.e009174.20","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"2025100306472086000_12.12.e009174.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.022"},{"key":"2025100306472086000_12.12.e009174.22","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain (Bacau)"},{"key":"2025100306472086000_12.12.e009174.23","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0582-9"},{"key":"2025100306472086000_12.12.e009174.24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment\u2013associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"key":"2025100306472086000_12.12.e009174.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2025100306472086000_12.12.e009174.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100306472086000_12.12.e009174.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100306472086000_12.12.e009174.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100306472086000_12.12.e009174.29","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025100306472086000_12.12.e009174.30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1434495","article-title":"EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma","volume":"14","author":"Sterner","year":"2024","journal-title":"Front Oncol"},{"key":"2025100306472086000_12.12.e009174.31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.229781"},{"key":"2025100306472086000_12.12.e009174.32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025100306472086000_12.12.e009174.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100306472086000_12.12.e009174.34","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1182\/blood-2022-165125","article-title":"Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines","volume":"140","author":"Marchetti","year":"2022","journal-title":"Blood"},{"key":"2025100306472086000_12.12.e009174.35","doi-asserted-by":"crossref","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Semin Immunopathol"},{"key":"2025100306472086000_12.12.e009174.36","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"PMCID","author":"Park","year":"2023","journal-title":"N Med"},{"key":"2025100306472086000_12.12.e009174.37","doi-asserted-by":"crossref","first-page":"1403145","DOI":"10.3389\/fimmu.2024.1403145","article-title":"Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin\u2019s lymphoma","volume":"15","author":"Frame","year":"2024","journal-title":"Front Immunol"},{"key":"2025100306472086000_12.12.e009174.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342"},{"key":"2025100306472086000_12.12.e009174.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00929-0","article-title":"Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma","volume":"13","author":"Sidana","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025100306472086000_12.12.e009174.40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-024-01542-9","article-title":"Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel","volume":"PMCID","author":"Ghilardi","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2025100306472086000_12.12.e009174.41","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"PMCID","author":"Ghilardi","year":"2022","journal-title":"Ann Oncol"},{"key":"2025100306472086000_12.12.e009174.42","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","article-title":"Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines","volume":"PMCID","author":"Ghilardi","year":"2024","journal-title":"Blood Adv"},{"key":"2025100306472086000_12.12.e009174.43","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ajh.27069","article-title":"Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma","volume":"PMCID","author":"Ong","year":"2023","journal-title":"Am J Hematol"},{"key":"2025100306472086000_12.12.e009174.44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100306472086000_12.12.e009174.45","doi-asserted-by":"crossref","unstructured":"Schuster SJ , et al . Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood 2017. doi:10.1002\/hon.2437_6","DOI":"10.1002\/hon.2437_6"},{"key":"2025100306472086000_12.12.e009174.46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(24)00815-8","article-title":"CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma","volume":"404","author":"Schubert","year":"2024","journal-title":"Lancet"},{"key":"2025100306472086000_12.12.e009174.47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162593","article-title":"Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing","volume":"134","author":"Appelbaum","year":"2024","journal-title":"J Clin Invest"},{"key":"2025100306472086000_12.12.e009174.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100306472086000_12.12.e009174.49","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2025100306472086000_12.12.e009174.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2"},{"key":"2025100306472086000_12.12.e009174.51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","article-title":"CAR-T cell therapy in AML: recent progress and future perspectives","volume":"120","author":"Saito","year":"2024","journal-title":"Int J Hematol"},{"key":"2025100306472086000_12.12.e009174.52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"2025100306472086000_12.12.e009174.53","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","article-title":"Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities","volume":"50","author":"Schroeder","year":"2024","journal-title":"Intensive Care Med"},{"key":"2025100306472086000_12.12.e009174.54","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12028-024-01995-3","article-title":"CAR-T Cell Therapy and the Neurointensivist","volume":"41","author":"Wijdicks","year":"2024","journal-title":"Neurocrit Care"},{"key":"2025100306472086000_12.12.e009174.55","doi-asserted-by":"crossref","DOI":"10.1186\/s42466-021-00166-5","article-title":"Neurological management and work-up of neurotoxicity associated with CAR T cell therapy","volume":"4","author":"M\u00f6hn","year":"2022","journal-title":"Neurol Res Pract"},{"key":"2025100306472086000_12.12.e009174.56","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002550"},{"key":"2025100306472086000_12.12.e009174.57","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095921"},{"key":"2025100306472086000_12.12.e009174.58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301507"},{"key":"2025100306472086000_12.12.e009174.59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003486","article-title":"Time to evolve: predicting engineered T cell-associated toxicity with next-generation models","volume":"10","author":"Donnadieu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100306472086000_12.12.e009174.60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003487","article-title":"Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?","volume":"10","author":"Guedan","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:47:32Z","timestamp":1759499252000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,22]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/jitc-2024-009174"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009174","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}